Poor
Not Aligned
Patient Risk:
High
Summary
Most statements in the provided response are about rizatriptan (Relpax/“Relpax generic” substitution) and generic equivalence, while the supplied FDA label is for RELPAX (eletriptan). Therefore, multiple core claims are not supported by the supplied prescribing information and several statements are inconsistent with the labeled product.
Category Scores
Accurate Statements
Rizatriptan is marketed as rizatriptan benzoate.
Not supported by the provided RELPAX (eletriptan) label text.
Unsupported Statements
Relpax is a brand name used for the migraine drug rizatriptan.
The supplied label describes RELPAX as eletriptan hydrobromide, not rizatriptan.
The common “Relpax generic” term usually refers to rizatriptan in its generic form.
Not supported by the supplied label; label is for eletriptan (RELPAX), not rizatriptan.
Rizatriptan has generic versions available.
Generic availability is not addressed in the supplied label.
Pharmacies can often dispense a rizatriptan generic instead of the branded Relpax product.
The supplied label does not discuss pharmacy substitution rules or generic dispensing practices.
The specific dispensing of a rizatriptan generic instead of Relpax depends on the formulation and the prescriber’s instructions.
The supplied label does not address substitution, formulation requirements for dispensing, or prescriber instructions.
Generics use the same active ingredient (rizatriptan) as brand Relpax.
Not supported by the supplied label; the labeled brand RELPAX contains eletriptan hydrobromide.
Generics are expected to work the same way for most patients.
Not supported by the supplied label.
Differences between brand Relpax and rizatriptan generic may include the manufacturer.
Not addressed in the supplied label.
Differences between brand Relpax and rizatriptan generic may include tablet strength.
Not supported by the supplied label.
Differences between brand Relpax and rizatriptan generic may include inactive ingredients.
While the provided label lists inactive ingredients for RELPAX, the label does not state how generics differ versus the brand or address inactive-ingredient differences in that context.
Inactive ingredients can affect tolerability for a small number of people.
Not stated in the supplied label.
Rizatriptan tablets at the same mg strength as a Relpax prescription are commonly discussed as Relpax-equivalent generics.
Not supported by the supplied label and uses rizatriptan/Relpax equivalence not addressed in the label.
ODT (or dissolvable) vs standard tablet form may be relevant when comparing Relpax-equivalent generics if the original product is specified that way.
The supplied label describes oral tablets but does not discuss rizatriptan equivalency, ODT products, or substitution based on dosage form.
Dosing is typically the same with the generic if the active ingredient, strength, and formulation are the same.
Not supported by the supplied label.
Migraine drugs have limits based on total daily dose and timing between doses.
The label provided includes dosing limits for RELPAX (eletriptan), but the statement is generic and not tied to the labeled product’s specific regimen; additionally the surrounding response is about rizatriptan.
A pharmacist can often substitute Relpax with a generic under standard substitution rules.
Not addressed in the supplied label.
Whether a pharmacist can substitute depends on prescription wording.
Not addressed in the supplied label.
Whether a pharmacist can substitute depends on local pharmacy policies and availability.
Not addressed in the supplied label.
Whether a pharmacist can substitute depends on insurance formularies.
Not addressed in the supplied label.
Rizatriptan generics generally have the same safety profile as Relpax.
Not supported by the supplied label and conflates rizatriptan safety with RELPAX (eletriptan) labeling.
If switching, differences you personally notice may include stomach upset.
Not supported by the supplied label.
If switching, differences you personally notice may include tingling.
Not supported by the supplied label.
If switching, differences you personally notice may include flushing.
Not supported by the supplied label.
If switching, differences you personally notice may include dizziness.
Not supported by the supplied label.
Contradictions
High
AI Statement
Relpax is a brand name used for the migraine drug rizatriptan.
Label Reference
11 DESCRIPTION and overall product identity: RELPAX contains eletriptan hydrobromide (not rizatriptan).
High
AI Statement
Generics use the same active ingredient (rizatriptan) as brand Relpax.
Label Reference
11 DESCRIPTION: RELPAX contains eletriptan hydrobromide.
Important Omissions
No label-supported guidance was provided regarding RELPAX (eletriptan) indications and limitations of use (e.g., acute migraine treatment in adults; not intended for prevention; not for cluster headache; reconsider diagnosis if no response to first attack).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response’s central claims misidentify RELPAX as rizatriptan and discuss rizatriptan substitution/equivalence, which is not supported by the supplied RELPAX (eletriptan) label and could lead to incorrect interpretation of labeled directions/contraindications.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Confusion between RELPAX (eletriptan) and rizatriptan, and many assertions about generic substitution and comparative safety are not addressed in the supplied label.
Suggested Improvement
Limit claims to what is stated in the provided RELPAX (eletriptan) prescribing information (e.g., acute migraine indication and labeled dosing limits), and avoid rizatriptan/generic equivalence and pharmacy substitution statements unless explicitly supported by the provided label text.